The aim of this retrospective study was to compare efficacy and development of bacterial resistance with two different prophylaxis regimens over a time period of more than 4 years.
READ FULL ARTICLE
From Springer
Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia
the Oncology Nurse Advisor take:
Recent meta-analyses showed that incidence of fever and mortality rate were reduced in patients with neutropenia after chemotherapy when antibiotic prophylaxis was administered.
As fluoroquinolones appear to be most effective and well tolerated, a German team changed the antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).
In this retrospective study, they compare the efficacy and development of bacterial resistance with the two prophylaxis regimens over a period of more than 4 years via a standard questionnaire.
The findings show no significant difference in incidence of fever between the COT/COL group and the CIP group.
In addition, the rates of both microbiologically and clinically documented infections were similar, as well as rates of gram-positive and gram-negative bacteria.
No increases in resistance rates or cases with Clostridium difficile-associated diarrhea in the CIP group were noted.
The researchers conclude antibiotic prophylaxis with CIP and COT/COL in patients with AML was similarly effective with no increase in bacterial resistance.
